Theobald is dedicated to harnessing the therapeutic potential of live bacteria for the treatment of cancer. Based on historical knowledge of the ability of bacteria to result in complete cancer remissions and discoveries at the Yale Medical School of Salmonella’s ability to target tumors, Theobald is dedicated to bringing novel tumor-targeted bacterial therapies to the clinic. 

 

Theobald’s lead product candidate is based upon VNP20009 engineered to deliver combination of an immunotherapeutic cytotoxin combined with a protease inhibitor. Through targeted delivery, greater activity is achieved with lower toxicity. Our lead therapeutic candidate selectively targets the EGFR pathway that is overexpressed in a subset of triple negative breast cancer as well as in other cancers including lung, colon, bladder, kidney, head and neck, and prostate cancers. The therapeutic effect is enhanced by being protected from tumor proteases that destroy therapeutic proteins.